| Arthur Dwight Sandy, MD | |
|
810 Saint Vincents Dr, Birmingham, AL 35205-1601 | |
| (205) 939-7855 | |
| (205) 824-8111 |
| Full Name | Arthur Dwight Sandy |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 42 Years |
| Location | 810 Saint Vincents Dr, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083677173 | NPI | - | NPPES |
| 009985115 | Medicaid | AL | |
| 51522880 | Other | AL | BLUE CROSS BLUE SHIELD |
| 51520585 | Other | AL | BLUE CROSS/BLUE SHIELD |
| 51520584 | Other | AL | BLUE CROSS/BLUE SHIELD |
| 000084922 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 17046 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Vincent's Birmingham | Birmingham, AL | Hospital |
| Brookwood Baptist Medical Center | Birmingham, AL | Hospital |
| Riverview Regional Medical Center | Gadsden, AL | Hospital |
| Russell Medical Center | Alexander city, AL | Hospital |
| Usa Health University Hospital | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coastal Neurological Institute Pc | 4688617699 | 18 |
| Radiology Associates Of Birmingham, P.c. | 7214928571 | 37 |
| Radiology Associates Of Birmingham, P.c. | 7214928571 | 37 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
| Entity Name | Norwood Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104879741 PECOS PAC ID: 8921996364 Enrollment ID: O20040308001107 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
| Entity Name | Radiology Associates Of Birmingham, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093778706 PECOS PAC ID: 7214928571 Enrollment ID: O20040524001193 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
| Entity Name | Coastal Neurological Institute Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740212174 PECOS PAC ID: 4688617699 Enrollment ID: O20050609000711 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
| Entity Name | St Vincents Ambulatory Healthcare Network Llc |
|---|---|
| Entity Type | Part B Supplier - Independent Diagnostic Testing Facility (idtf) |
| Entity Identifiers | NPI Number: 1588190441 PECOS PAC ID: 1355608456 Enrollment ID: O20171128001387 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
| Entity Name | St Vincents Ambulatory Healthcare Network Llc |
|---|---|
| Entity Type | Part B Supplier - Independent Diagnostic Testing Facility (idtf) |
| Entity Identifiers | NPI Number: 1033646823 PECOS PAC ID: 1355608456 Enrollment ID: O20180626000597 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
| Entity Name | Cooper Green Mercy Health Services Authority An Affiliate Of Uab |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366073108 PECOS PAC ID: 0840629473 Enrollment ID: O20200402003238 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
| Entity Name | Southern Orthopaedic Alliance Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588364228 PECOS PAC ID: 2365800604 Enrollment ID: O20230620001264 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Arthur Dwight Sandy, MD 2090 Columbiana Rd, Suite 4400, Birmingham, AL 35216-2153 Ph: (205) 824-8000 | Arthur Dwight Sandy, MD 810 Saint Vincents Dr, Birmingham, AL 35205-1601 Ph: (205) 939-7855 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal DM chewable tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg, Dextromothorphan HBr 15 mg) are new drugs lacking an approved application and as such should not be introduced into interstate commerce.
Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
News outlets report on payment issues for hospitals, including those stemming from the new health law.
Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.
Finding out where gene-regulator proteins bind to DNA and identifying the genes they regulate just got a step easier thanks to a new technique developed by scientists at the U.S. Department of Energy's Brookhaven National Laboratory.
› Verified 2 days ago
Dr. Garrett Colby, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Jt N342, Birmingham, AL 35249 Phone: 205-934-3108 Fax: 205-975-4413 | |
Drexell H Boggs, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1700 6th Ave S, Rm: 2253, Birmingham, AL 35233 Phone: 205-975-9399 Fax: 205-975-5184 | |
James Walker, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Joseph Smith, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Michelle M Mcnamara, MD Radiology Medicare: Medicare Enrolled Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-4011 | |
Sharda Mehar Bajaj, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1526 5th Ave S, Birmingham, AL 35233 Phone: 205-279-2860 | |
Gina Elizabeth Rebesco, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 625 19th St S, Birmingham, AL 35233 Phone: 205-975-0222 |